TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25801553

Group type: EXPERIMENTAL
Intervention: 15.0 mg of sublingual artemether (5 × 3.0 actuations)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 30.0 mg of sublingual artemether (10 × 3.0 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 30.0 mg of sublingual artemether (5 × 6.0 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 30.0 mg of artemether in tablet form
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 30.0 mg of sublingual artemether given over 5 days as either 10 3.0‐mg or 5 6.0‐mg actuations
Number of subjects: 16
Study: 23711188

Group type: EXPERIMENTAL
Intervention: Sitagliptin daily for 28 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21850387

Group type: EXPERIMENTAL
Intervention: Olmesartan (20 mg, range 10-40 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (no olmesartan)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Olmesartan and Control
Number of subjects: 48
Study: 19272375

Group type: EXPERIMENTAL
Intervention: 3 x 250 mg naproxen
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 3 x 50 mg diclofenac
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 3 x 1 g acetaminophen
Number of subjects: 11

Group type: COMPARATOR
Intervention: 3 x 1 placebo
Number of subjects: 11
Study: 17236771

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (CT)
Number of subjects: 2208

Group type: EXPERIMENTAL
Intervention: Mastectomy (Mx)
Number of subjects: 2208

Group type: EXPERIMENTAL
Intervention: Wide local excision (WLE)
Number of subjects: 2208

Group type: EXPERIMENTAL
Intervention: Endocrine therapy (ET)
Number of subjects: 2208

Group type: EXPERIMENTAL
Intervention: Age <50 years (proxy pre-menopausal)
Number of subjects: 2208

Group type: EXPERIMENTAL
Intervention: Overall QOL and mental health
Number of subjects: 2208
Study: 15709456

Group type: EXPERIMENTAL
Intervention: Montelukast (MON; 10 mg daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Zafirlukast (ZAF; 40 mg daily)
Number of subjects: 40
Study: 12191965

Group type: EXPERIMENTAL
Intervention: Serum creatinine levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proteinuria (none, trace, overt)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum uric acid levels
Number of subjects: 0
Study: 9737821

Group type: EXPERIMENTAL
Intervention: 30 mg oral controlled release tablet (A)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20 mg aqueous solution retained in the mouth for 10 min (B)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 60 mg bioadhesive buccal tablet placed between the lower gum and lip for 6 h (C)
Number of subjects: 12
Study: 7856622

Group type: EXPERIMENTAL
Intervention: Venlafaxine (75-375 mg/day in two or three divided doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 0
Study: 2563045

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch (30 cm2 for heavy smokers, 20 cm2 for others)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Number of subjects: 199
Study: 808082

Group type: EXPERIMENTAL
Intervention: sodium cromoglycate
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 23
Study: 30817455

Group type: EXPERIMENTAL
Intervention: Cardiac CT
Number of subjects: 1347

Group type: EXPERIMENTAL
Intervention: ECG
Number of subjects: 1347

Group type: EXPERIMENTAL
Intervention: Combination of Sokolow‐Lyon index, Cornell voltage duration product, and/or Romhilt‐Estes score at least 4
Number of subjects: 1347

Group type: COMPARATOR
Intervention: CT signs of LVH
Number of subjects: 1347
Study: 28802512

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 10939

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 10939
Study: 25935843

Group type: EXPERIMENTAL
Intervention: Functional motor control exercise
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Isolated hip abductor strengthening
Number of subjects: 29
Study: 24174667

Group type: EXPERIMENTAL
Intervention: Ongoing task load during the delay
Number of subjects: 0

Group type: COMPARATOR
Intervention: Task-free delays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall encoding of delayed intentions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rostrolateral PFC (BA 46)
Number of subjects: 0
Study: 23939305

Group type: EXPERIMENTAL
Intervention: Bradykinesia subscale alone group (n = 56)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Full scale group (n = 56)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both groups (bradykinesia subscale alone and full scale)
Number of subjects: 112
Study: 19917367

Group type: EXPERIMENTAL
Intervention: Equimolar enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 25
Study: 17909129

Group type: EXPERIMENTAL
Intervention: Family-based intervention (22 weekly group sessions for parents and preschoolers and 10 biweekly home visits over 6-8 months)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 92
Study: 15049991

Group type: EXPERIMENTAL
Intervention: 1 g of 1% testosterone gel applied once or twice daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 3 g of 2% testosterone gel applied once daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 2% testosterone gel applied once daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1 g of 2% testosterone gel applied once or twice daily
Number of subjects: 18
Study: 11574416

Group type: EXPERIMENTAL
Intervention: Hypoglycemia (plasma glucose levels of 2.6 mmol/l) in hypoglycemia-unaware patients
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Hypoglycemia (plasma glucose levels of 2.6 mmol/l) in hypoglycemia-aware patients
Number of subjects: 13
Study: 9663185

Group type: EXPERIMENTAL
Intervention: 200 mg S(+)-ibuprofen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 400 mg S(+)-ibuprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: 400 mg racemic ibuprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7816992

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg qid)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 2660555

Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g twice daily
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study: 4559028

Group type: EXPERIMENTAL
Intervention: Opipramol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30027389

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 236
Study: 28894822

Group type: EXPERIMENTAL
Intervention: Olfactory training (OT) using essential oils at random concentrations for 6 months
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no olfactory training)
Number of subjects: 35
Study: 26223821

Group type: EXPERIMENTAL
Intervention: Incentive offered (up to $50)
Number of subjects: 1850

Group type: COMPARATOR
Intervention: No incentive offered
Number of subjects: 1850
Study: 21883718

Group type: EXPERIMENTAL
Intervention: Tailored educational intervention (2-day interactive workshop for higher readiness GPs and 2-day large group meeting for lower readiness GPs)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Standard educational programme on the same topic (Control)
Number of subjects: 192
Study: 21786177

Group type: EXPERIMENTAL
Intervention: Vernakalant 3 mg/kg IV infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vernakalant 2 mg/kg IV infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18609080

Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg once daily
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study: 16869719

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg/day
Number of subjects: 308

Group type: COMPARATOR
Intervention: Tamoxifen 20 mg/day
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Combination treatment with anastrozole and tamoxifen
Number of subjects: 308
Study: 16130345

Group type: EXPERIMENTAL
Intervention: CD-ROM tutorial on HIPAA along with a journal article on HIPAA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Text-directed self-study method (control group)
Number of subjects: 0
Study: 12950664

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Chloroquine plus chlorpheniramine (CQCP)
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Chloroquine plus ketotifen (CQK)
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Chloroquine plus pyrimethamine-sulphadoxine (CQPS)
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Amodiaquine plus pyrimethamine-sulphadoxine (AQPS)
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Pyrimethamine-sulphadoxine (PS)
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: CQ treatment of CQ-S infections
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: CQ treatment of CQ-R infections
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: CQ-R infections with mild resistance (RI)
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: CQ-R infections
Number of subjects: 710
Study: 10414010

Group type: EXPERIMENTAL
Intervention: Nurse Home Visitation Program
Number of subjects: 0
Study: 7675863

Group type: EXPERIMENTAL
Intervention: Flumazenil (5.0 mg/70 kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.25, 0.5, and 1.0 mg/70 kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nitrous oxide (30% in oxygen for 35 min)
Number of subjects: 16
Study: 2142633

Group type: EXPERIMENTAL
Intervention: Sufentanil alone (1.0 micrograms.kg‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-dose sufentanil (0.5 micrograms.kg‐1) with lidocaine (1.5 mg.kg‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline infusion (C)
Number of subjects: 30
Study: 7383457

Group type: EXPERIMENTAL
Intervention: Progesterone vaginal suppositories
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 14

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 14
Study: 29464907

Group type: EXPERIMENTAL
Intervention: PAT plus a lifestyle intervention program (PAT+)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Standard PAT
Number of subjects: 267
Study: 27752287

Group type: EXPERIMENTAL
Intervention: Standard diabetic offloading insole made from EVA/poron®
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low resilient memory insole
Number of subjects: 50

Group type: COMPARATOR
Intervention: Textured insole
Number of subjects: 50

Group type: COMPARATOR
Intervention: Flat soft insole
Number of subjects: 50

Group type: COMPARATOR
Intervention: No insole
Number of subjects: 50
Study: 25667811

Group type: EXPERIMENTAL
Intervention: Pharmacist comprehensive medication management services (PCS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No pharmacist comprehensive medication management services (NCS)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 120
Study: 23063027

Group type: EXPERIMENTAL
Intervention: Basal/Bolus regimen with glargine/glulisine (n = 169)
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Basal/Bolus regimen with detemir/aspart (n = 67)
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Basal/Bolus regimen with neutral protamine Hagedorn/regular (n = 63)
Number of subjects: 472

Group type: COMPARATOR
Intervention: Regular sliding scale insulin (SSI) (n = 173)
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Medical patients
Number of subjects: 472

Group type: COMPARATOR
Intervention: Surgical patients
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Impaired kidney function (glomerular filtration rate < 60 ml/min)
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Total daily insulin dose
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Type of insulin regimen (basal/bolus versus SSI)
Number of subjects: 472
Study: 19544136

Group type: EXPERIMENTAL
Intervention: Daily reports of vaginal sex
Number of subjects: 376

Group type: COMPARATOR
Intervention: Retrospective reports of vaginal sex
Number of subjects: 376
Study: 18762516

Group type: EXPERIMENTAL
Intervention: Early antibiotic treatment (within <1 day of fever onset)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Delayed antibiotic treatment (>/=5 days after fever onset)
Number of subjects: 287
Study: 17179056

Group type: EXPERIMENTAL
Intervention: Black cohosh, 160 mg daily
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Multibotanical with black cohosh, 200 mg daily, and 9 other ingredients
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Multibotanical plus dietary soy counseling
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen, 0.625 mg daily, with or without medroxyprogesterone acetate, 2.5 mg daily
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study: 14529055

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 2.5 mg orally disintegrating tablet (ODT)
Number of subjects: 218
Study: 11004622

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel
Number of subjects: 10

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 10
Study: 8827316

Group type: EXPERIMENTAL
Intervention: Functional knee braces
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Functional knee braces with lower extremity muscle activation
Number of subjects: 5
Study: 1420010

Group type: EXPERIMENTAL
Intervention: Epoprostenol (n = 22)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Dihydralazine (n = 25)
Number of subjects: 47
Study: 6699312

Group type: EXPERIMENTAL
Intervention: Aminophylline therapy added to metaproterenol sulfate and beclomethasone dipropionate aerosol therapy
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Aminophylline therapy added to metaproterenol sulfate aerosol
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Aminophylline therapy
Number of subjects: 21
Study: 31056291

Group type: EXPERIMENTAL
Intervention: Gentamicin 240 mg
Number of subjects: 720

Group type: COMPARATOR
Intervention: Ceftriaxone 500 mg
Number of subjects: 720
Study: 29524005

Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy
Number of subjects: 0
Study: 26760077

Group type: EXPERIMENTAL
Intervention: Pedestrian safety training sessions (6 sessions of 45 crossings each) in a virtual environment
Number of subjects: 59
Study: 24486635

Group type: EXPERIMENTAL
Intervention: Multi-modal educational (MME) intervention including traditional education (TE) approaches, a web-based course, and preceptor-facilitated training during a 3rd year clerkship rotation.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Traditional education (TE)
Number of subjects: 10
Study: 22677092

Group type: EXPERIMENTAL
Intervention: Nurse-led self-help treatment plus usual care
Number of subjects: 268

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 268
Study: 19818588

Group type: EXPERIMENTAL
Intervention: Rose-hip powder 5g daily
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 18311493

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CPAP (on nights)
Number of subjects: 12
Study: 15946834

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (800 microg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 12621381

Group type: EXPERIMENTAL
Intervention: Indinavir 1000 mg every 8 hours plus rifabutin 150 mg daily
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Rifabutin 150 mg daily with indinavir
Number of subjects: 28

Group type: COMPARATOR
Intervention: Rifabutin 300 mg daily alone
Number of subjects: 28
Study: 10344294

Group type: EXPERIMENTAL
Intervention: Test lenses with varying oxygen transmissibility
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Test lenses
Number of subjects: 109

Group type: COMPARATOR
Intervention: Baseline values of outcome measures
Number of subjects: 109
Study: 8559498

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) 5 mg/kg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) 4 mg/kg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) 3 mg/kg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) 2 mg/kg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 7
Study: 2387651

Group type: EXPERIMENTAL
Intervention: PPA 25 mg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: PPA 15 mg
Number of subjects: 180

Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 180
Study: 6789951

Group type: EXPERIMENTAL
Intervention: Multiple-gated blood-pool imaging
Number of subjects: 32

Group type: COMPARATOR
Intervention: Contrast ventriculography
Number of subjects: 32
Study: 31850778

Group type: EXPERIMENTAL
Intervention: Conventional toothbrush
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Silicone tooth and gum brush
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Parents brushing with conventional toothbrush
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Parents brushing with silicone tooth and gum brush
Number of subjects: 9

Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 9
Study: 30001727

Group type: EXPERIMENTAL
Intervention: Lotilaner (Credelio™) administered orally at a dose of 6 mg/kg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Negative control (no treatment)
Number of subjects: 16
Study: 26717057

Group type: EXPERIMENTAL
Intervention: Quantitative immunofluorescence (QIF) model
Number of subjects: 2919

Group type: COMPARATOR
Intervention: Conventional 3,3'-diaminobezidine (DAB) immunohistochemistry model
Number of subjects: 2919
Study: 24892113

Group type: EXPERIMENTAL
Intervention: NobelActive implants (Nobel Biocare)
Number of subjects: 34

Group type: COMPARATOR
Intervention: NobelSpeedy Groovy implants (Nobel Biocare)
Number of subjects: 34
Study: 21512834

Group type: EXPERIMENTAL
Intervention: Parent-mediated communication-focused treatment for autism
Number of subjects: 28

Group type: COMPARATOR
Intervention: Ordinary care
Number of subjects: 28
Study: 20079528

Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg loading dose followed by 90 mg twice a day)
Number of subjects: 18624

Group type: COMPARATOR
Intervention: Clopidogrel (300-600 mg loading dose or continuation with maintenance dose followed by 75 mg per day)
Number of subjects: 18624

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 18624

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 18624
Study: 18003434

Group type: EXPERIMENTAL
Intervention: Alprazolam (different doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15672272

Group type: EXPERIMENTAL
Intervention: Estradiol (2 mg estradiol valerate)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Estradiol plus progesterone (100 mg micronized progesterone)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 12183095

Group type: EXPERIMENTAL
Intervention: Comprehensive palliative care program
Number of subjects: 180

Group type: COMPARATOR
Intervention: Conventional care program (control)
Number of subjects: 180
Study: 9915533

Group type: EXPERIMENTAL
Intervention: Prazosin 1 mg orally 12 hours before surgery, just before surgery, and 12 and 24 hours after surgery
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo orally 12 hours before surgery, just before surgery, and 12 and 24 hours after surgery
Number of subjects: 156
Study: 8740302

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (1 g/m2 per day divided into two equal doses)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation
Number of subjects: 69
Study: 1655847

Group type: EXPERIMENTAL
Intervention: Coping skills training
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Interactional therapy
Number of subjects: 96
Study: 6227304

Group type: EXPERIMENTAL
Intervention: Self-Hypnosis (n = 9)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Relaxation (n = 8)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 17
Study: 29068267

Group type: EXPERIMENTAL
Intervention: Two-stage (TS) palatal repair
Number of subjects: 33

Group type: COMPARATOR
Intervention: One-stage (OS) palatal repair
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both TS and OS groups
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Early intervention (not part of the trial)
Number of subjects: 33
Study: 29443788

Group type: EXPERIMENTAL
Intervention: Repeated-doses RSB analgesia
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study: 26721259

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg/day for 21 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg/day
Number of subjects: 25
Study: 23088350

Group type: EXPERIMENTAL
Intervention: α1 noradrenergic blockers + α2 noradrenergic agonists
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: benzodiazepines
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: voltage-sensitive sodium channel anticonvulsants
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: α2δ voltage-sensitive calcium channel blockers
Number of subjects: 408
Study: 22265143

Group type: EXPERIMENTAL
Intervention: Corneal cross‐linking (CXL) with riboflavin and ultraviolet A (UVA) light
Number of subjects: 39

Group type: COMPARATOR
Intervention: Riboflavin 0.1% (w/v) eyedrops - 20% dextran solution for 1 month
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CXL and riboflavin eyedrops
Number of subjects: 39
Study: 19789444

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gelofusine (4% succinylated gelatin in 0.7% saline)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Voluven (6% hydroxyethyl starch in 0.9% saline)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 10